Abstract
No public abstract is available from the verified source records.
Gulshan Aliyeva, Sezan Mergen Kılıç, Zuhal Yapıcı, Pınar Topaloğlu
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Indirect estimation of the prevalence of spinal muscular atrophy type I, II, and III in the United States
10.1186/s13023-017-0724-z · 2017
Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy–a literature review
10.1186/s13023-017-0671-8 · 2017
Carrier frequency of spinal muscular atrophy in Turkish population
10.2399/prn.22.0301012 · 2022
Spinal muscular atrophy
10.1038/s41572-022-00380-8 · 2022
Spinal muscular atrophy
10.1016/j.spen.2021.100878 · 2021
The Children’s Hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability
10.1016/j.nmd.2009.11.014 · 2010
An expanded version of the Hammersmith functional motor scale for SMA II and III patients
10.1016/j.nmd.2007.05.009 · 2007
Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study
10.1016/s1474-4422(20)30037-5 · 2020
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
10.1002/acn3.51411 · 2021
Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3
10.1136/jnnp-2020-323822 · 2020
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis
10.1186/s13023-021-02065-z · 2021
Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience
10.1186/s13023-023-02769-4 · 2023
Effectiveness of Nusinersen in adolescents and adults with spinal muscular atrophy: systematic review and Meta-analysis
10.1007/s40120-024-00653-2 · 2024
Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland
10.1016/j.nmd.2022.02.001 · 2022
Real-world data on the effect of long-term treatment with nusinersen over> 4 years in a cohort of Swiss patients with spinal muscular atrophy
10.1016/j.clineuro.2025.108983 · 2025
Nusinersen for adults with spinal muscular atrophy
10.1007/s10072-023-06698-9 · 2023
No additional external references are available.